Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?

Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?


Could Mavyret deliver a big blow to Gilead Sciences' hopes for higher hepatitis C sales? Hepatitis C treatment has taken big steps forward over the past decade. Previous treatments including the side effect-causing drugs peg interferon and ribavirin have been replaced by next-generation drugs that deliver functional cure rates that are above 90% in as few as 12 weeks, and in some patients, as little as eight weeks.



from Biotech News